Alectinib Provides a New Option for ALK-positive NSCLC Patients After Progression on Crizotinib
Journal of Community and Supportive Oncology - United States
doi 10.12788/jcso.0277
Full Text
Open PDFAbstract
Available in full text
Date
June 1, 2016
Authors
Publisher
Frontline Medical Communications, Inc.